Source - RNS
RNS Number : 9227L
Lifeline Scientific, Inc
06 October 2016
 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

Lifeline Scientific, Inc.
("LSI" or the "Company")

 

RESULTS OF SPECIAL MEETING

 

Lifeline Scientific, Inc. (AIM: LSIC), a leading international provider of clinical products and services in the field of transplantation, announces that at the special meeting of LSI's stockholders held today at 9.00 a.m. local time (US CDT) all resolutions were duly passed and approved. This included resolutions to:

 

1.            adopt the agreement and plan of merger entered into with Shanghai Genext Medical Technology Co., Ltd. and certain of its affiliates (the "Merger Agreement" and the transaction provided for therein, the "Merger"); and

 

2.            approve the cancellation of the admission of LSI's common stock to trading on the AIM market of the London Stock Exchange plc ("AIM") conditional on closing of the Merger (the "Cancellation").

 

The closing of the Merger is still subject to regulatory review and certain other customary closing conditions as provided for in the Merger Agreement. At least twenty business days prior to the effective time of the Merger, the Company intends to make an application to the London Stock Exchange plc for the Cancellation to take effect from 7.00 a.m. (UK time) on the next business day after the date of the effective time of the Merger. It is currently expected that closing will occur no later than 9 December 2016 (subject to extension under certain circumstances).  

 

LSI will announce further details of the Cancellation timetable in due course. It is expected that the last day of dealing in LSI's common stock prior to their cancellation from trading on AIM and the last day for registration of transfers of LSI's common stock will be the date of the effective time of the Merger. No transfers of LSI's common stock will be registered after that time and date.  All of LSI's shares of common stock and the depositary interests representing such common stock held in CREST will be cancelled with effect from the effective time of the Merger.

 

For further information:

 

Lifeline Scientific, Inc.

www.lifeline-scientific.com

David Kravitz, CEO

Tel: +1 847 294 0300

Lisa Kieres, CFO

Tel: +1 847 294 0300

 

 

Piper Jaffray Ltd. (Financial Adviser to LSI)

Tel: +44 (0)20 7796 8400

Neil Mackison / Graeme Smethurst

 

 

 

Panmure Gordon (UK) Limited

Tel: +44 (0)20 7886 2500

Freddy Crossley / Duncan Monteith (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

     

 

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZQLFBQBFFFBD

Related Charts

Lifeline Scientific Inc (LSIC)

-1.50p (-0.48%)
delayed 18:15PM